3 stocks that soared stupendously this week 7-3-14


Published on

3 of the past week's biggest health-care stocks

1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849
  • 3 stocks that soared stupendously this week 7-3-14

    1. 1. 3 Stocks That Soared Stupendously This Week
    2. 2. The 4th of July brought plenty of fireworks – but the days leading up to the nation’s birthday brought other types of excitement. Here are three health-care stocks that soared and sizzled.
    3. 3. Shares of the biotech jumped 12% higher for the week. Regeneron Pharmaceuticals (NASDAQ:REGN) Source: Yahoo! Finance
    4. 4. • French drugmaker Sanofi (NYSE:SNY) announced on Tuesday that it was increasing its stake in Regeneron • This move gives Sanofi a 22.5% stake in Regeneron – up from 20.5% • Sanofi’s decision follows a recommendation last week by the European Committee for Medicinal Products, or CHMP, for approval of Eylea in treating visual impairment due to diabetic macular edema • Regeneron and Sanofi are collaborating on eight human monoclonal antibodies Why Regeneron shares were rejuvenated
    5. 5. Shares of the biopharmaceutical company shot up 16% higher this week. TG Therapeutics (NASDAQ:TGTX) Source: Yahoo! Finance
    6. 6. • TG Therapeutics benefited from positive comments from investment firm MLV & Co. on Wednesday • MLV reiterated its “buy” rating and raised the price target for TG from $10 to $16 because of the biotech’s solid pipeline • Shares of TG Therapeutics received a big boost last week after the company announced a global licensing deal with Ligand Pharmaceuticals (NASDAQ:LGND) • Ligand exchanged licensing rights for its IRAK4 inhibitor for 125,000 shares of TG – with the deal adding more depth to TG’s pipeline Why TG’s stock took off
    7. 7. Shares of the biopharmaceutical firm surged 32% this week. Amicus Therapeutics (NASDAQ:FOLD) Source: Yahoo! Finance
    8. 8. • Amicus gave an update on a clinical study of migalastat on Monday • While top-line results won’t be released until third quarter, the final patient completed the 18-month treatment period with all but one of 32 patients opting to continue receiving the drug in the 12-month extension study • The news generated excitement in the analyst community, with JP Morgan, Janny, and Leerink Partners upgrading Amicus and increasing price targets Why Amicus shares received a friendly bump
    9. 9. • There’s plenty to like about all three stock’s prospects • Amicus could have a bright future with migalastat, while Regeneron keeps on rocking with Eylea • The nod for most room to run, though, goes to TG Therapeutics • TG’s ublituximab and TGR-1202 could be winners, while the licensing deal with Ligand gives the company another path to success • More positive clinical results could make TG an attractive acquisition target for bigger drugmakers Best pick to keep soaring?
    10. 10. Cable’s going away. But do you know how to profit? There’s $2.2 trillion at stake. Find out which 3 companies stand ready to benefit -- and they’re not Netflix, Google, and Apple!